Clinical Trial Update: Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase II neoadjuvant pembrolizumab trial for early-stage gastroesophageal junction, gastric, and esophageal adenocarcinoma has been terminated with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Chicago | Conditions: Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-05-20